Teva won't say whether R&D cuts include layoffs; Cipla inks deal for Iranian plant;

teva logo

@FiercePharma: Top-read special report Monday: Top 10 pharma companies by employees - 2014. Feature | Follow @FiercePharma

@CarlyHFierce: One more time: Our latest special report, Top women in biotech 2014. Good stuff right here. Feature | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) won't yet say how many jobs might be affected by its plans to ratchet back R&D in women's health and oncology. Report

> Regeneron's ($REGN) ophthalmic injection Eylea won FDA approval for yet another indication, this time in patients with macular edema folowing retinal vein occlusion. Release

> Indian generics maker Cipla inked a partnership to set up a manufacturing plant in Iran, as part of a strategy to boost its presence there and expand far beyond its home market. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Optos, NHS and academia in $16M partnership for eye disease diagnostic. Article | Follow @FierceMedDev

@VarunSaxena2: Larry Wood of Edwards "Everybody's embarrassed that we were the 43rd country to get TAVR." Around same time as Brazil, Albania. | Follow @VarunSaxena2

@EmilyWFierce: Scalability and cost could be potential hurdles to bringing experimental CAR T-cell therapies to patients. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: From our Women in Biotech Feature: Adelene Perkins of $INFI says, "Our endeavor is by definition a team sport." More | Follow @MichaelGFierce

> NanoString teams up with Brigham and Women's Hospital for cancer Dx development. More

> Unilife inks 15-year deal with Sanofi for wearable injectors. Story

> GE promotes biz dev exec to head healthcare. Report

Biotech News

@FierceBiotech: Every year Women in Biotech gets a ton of readers, and this issue is no exception. Trending nicely. Report | Follow @FierceBiotech

@JohnCFierce: In a surprise move, Bristol-Myers drops U.S. approval plans for hep C drug. News | Follow @JohnCFierce

@DamianFierce: CRO INC Research files for a $150M IPO, following in the footsteps of $Q, $CTLT and PRA. SEC filing | Follow @DamianFierce

@EmilyMFierce: Programmed antibiotics kill drug-resistant bacteria. More from FierceBiotech Research | Follow @EmilyMFierce

> Another CRO heads to Wall Street as INC swings for $150M. Report

> Bellicum puts up $50M for Ariad's R&D tech. Item

> Positive PhIII PONV study brings little Acacia to a crossroads. Story

> With help from Eli Lilly, TVM pushes its build-to-buy fund to $201M. News

Biotech Research News

> NIH doles out first $46M round of BRAIN Initiative grants. Report

> Gene therapy technique could treat rare lung disease. More

> Programmed antibiotics kill drug-resistant bacteria. Story

> Ebola genome browser launched to aid drug discovery. Article

> $19M in FDA grants will support rare disease research. Item

Pharma Manufacturing News

> Cipla works with partner to build a manufacturing plant in Iran. More

> West Pharmaceutical confirms it's building $126M facility in Ireland. Story

> Patheon to add almost 500 jobs over 5 years as it expands in NC. Article

> India's IPCA buys plant as it deals with FDA issues. Item

> New FDA concerns arise for Hospira plant in Australia. Report

And Finally... Sucampo Pharmaceuticals ($SCMP) said its CFO, Cary Claiborne, would be leaving the company as of Nov. 7; a successor hasn't yet been named. Release